Literature DB >> 26260625

Preferences for anticoagulation therapy in atrial fibrillation: the patients' view.

Björn Böttger1, Inga-Marion Thate-Waschke2, Rupert Bauersachs3,4, Thomas Kohlmann5, Thomas Wilke6.   

Abstract

Since the introduction of new oral anticoagulants (NOACs), besides vitamin-K antagonists, an additional option for stroke prevention of patients with atrial fibrillation (AF) is available. The objective of this study was to assess AF patients' preferences with regard to the attributes of these different treatment options. We conducted a multicenter study among randomly selected physicians. Preferences were assessed by computer-assisted telephone interviews. We used a discrete-choice-experiment (DCE) with four convenience-related treatment dependent attributes (need of bridging: yes/no, interactions with food/nutrition: yes/no, need of INR controls/dose adjustment: yes/no; frequency of intake: once/twice daily) and one comparator attribute (distance to practitioner: <1 km/>15 km). Preferences measured in the interviews were analyzed descriptively and based on a conditional logit regression model. A total of 486 AF patients (age: 73.9 ± 8.2 years; 43.2 % female; mean CHA2DS2-VASc: 3.7 ± 1.6; current medication: 48.1 % rivaroxaban, 51.9 % VKA) could be interviewed. Regardless of type of medication, patients significantly preferred the attribute levels (in order of patients' importance) "once daily intake" (Level: once = 1 vs. twice = 0; Coefficient = 0.615; p < 0.001), "bridging necessary" (yes = 1 vs. no = 0; -0.558; p < 0.001), "distance to practitioner of ≤1 km (>15 km = 0 vs. ≤1 km = 1; 0.494; p < 0.001), "interactions with food/nutrition" (yes = 1 vs. no = 0; -0.332; p < 0.001) and "need of INR controls/dose adjustment" (yes = 1 vs. no = 0; -0.127; p < 0.001). In our analyses, "once daily frequency of intake" was the most important OAC-attribute for patients' choice followed by "no bridging necessary" and "no interactions with food/nutrition". Thus, patients with AF seem to prefer treatment options which are easier to administer.

Entities:  

Keywords:  Anticoagulation therapy; Atrial fibrillation; Discrete-choice design; Patients’ preferences

Mesh:

Substances:

Year:  2015        PMID: 26260625     DOI: 10.1007/s11239-015-1263-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  35 in total

Review 1.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Samantha MacLean; Sohail Mulla; Elie A Akl; Milosz Jankowski; Per Olav Vandvik; Shanil Ebrahim; Shelley McLeod; Neera Bhatnagar; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Patients' and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis.

Authors:  Christian Borg Xuereb; Rachel L Shaw; Deirdre A Lane
Journal:  Patient Educ Couns       Date:  2012-06-26

3.  The management of atrial fibrillation: summary of updated NICE guidance.

Authors:  Clare Jones; Vicki Pollit; David Fitzmaurice; Campbell Cowan
Journal:  BMJ       Date:  2014-06-19

Review 4.  Epidemiology and significance of atrial fibrillation.

Authors:  K M Ryder; E J Benjamin
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

Review 5.  Epidemiology and natural history of atrial fibrillation: clinical implications.

Authors:  S S Chugh; J L Blackshear; W K Shen; S C Hammill; B J Gersh
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

6.  Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation.

Authors:  B F Gage; A B Cardinalli; D K Owens
Journal:  Stroke       Date:  1998-06       Impact factor: 7.914

7.  Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese.

Authors:  Kuo-Liong Chien; Ta-Chen Su; Hsiu-Ching Hsu; Wei-Tien Chang; Pei-Chung Chen; Ming-Fong Chen; Yuan-Teh Lee
Journal:  Int J Cardiol       Date:  2008-11-30       Impact factor: 4.164

8.  Patient preferences and willingness to pay for different options of anticoagulant therapy.

Authors:  Marco Moia; Lorenzo Giovanni Mantovani; Monica Carpenedo; Luciana Scalone; Mara Silvia Monzini; Giancarlo Cesana; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2012-08-28       Impact factor: 3.397

9.  Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation.

Authors:  Jiyoon C Choi; Marco D Dibonaventura; Lewis Kopenhafer; Winnie W Nelson
Journal:  Patient Prefer Adherence       Date:  2014-02-07       Impact factor: 2.711

10.  Patient perspective on the management of atrial fibrillation in five European countries.

Authors:  Ameet Bakhai; Anna Sandberg; Thomas Mittendorf; Wolfgang Greiner; André M S Oberdiek; Patrizia Berto; Edith Franczok; Trudie Lobban; Jose L Zamorano
Journal:  BMC Cardiovasc Disord       Date:  2013-12-01       Impact factor: 2.298

View more
  15 in total

1.  Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients.

Authors:  Thomas Wilke; Antje Groth; Andreas Fuchs; Matthias Pfannkuche; Ulf Maywald
Journal:  Eur J Clin Pharmacol       Date:  2017-08-05       Impact factor: 2.953

Review 2.  Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.

Authors:  Alpesh Amin
Journal:  Ochsner J       Date:  2016

3.  Simulation study to determine the impact of different design features on design efficiency in discrete choice experiments.

Authors:  Thuva Vanniyasingam; Charles E Cunningham; Gary Foster; Lehana Thabane
Journal:  BMJ Open       Date:  2016-07-19       Impact factor: 2.692

4.  Heterogeneity in Preferences for Anti-coagulant Use in Atrial Fibrillation: A Latent Class Analysis.

Authors:  Janine van Til; Catharina Oudshoorn-Groothuis; Marieke Weernink; Clemens von Birgelen
Journal:  Patient       Date:  2020-08       Impact factor: 3.883

5.  Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis.

Authors:  Marieke G M Weernink; Melissa C W Vaanholt; Catharina G M Groothuis-Oudshoorn; Clemens von Birgelen; Maarten J IJzerman; Janine A van Til
Journal:  Am J Cardiovasc Drugs       Date:  2018-12       Impact factor: 3.571

6.  Discrete Choice Experiments in Health Economics: Past, Present and Future.

Authors:  Vikas Soekhai; Esther W de Bekker-Grob; Alan R Ellis; Caroline M Vass
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

Review 7.  Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review.

Authors:  Thomas Wilke; Sabine Bauer; Sabrina Mueller; Thomas Kohlmann; Rupert Bauersachs
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

8.  Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed.

Authors:  Herbert J A Rolden; Angela H E M Maas; Gert Jan van der Wilt; Janneke P C Grutters
Journal:  BMC Cardiovasc Disord       Date:  2017-10-13       Impact factor: 2.298

9.  COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study.

Authors:  Alexander T Cohen; Anthony Maraveyas; Jan Beyer-Westendorf; Agnes Y Y Lee; Lorenzo G Mantovani; Miriam Bach
Journal:  Thromb J       Date:  2018-09-04

10.  Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis.

Authors:  Deirdre A Lane; Juliane Meyerhoff; Ute Rohner; Gregory Y H Lip
Journal:  Clin Cardiol       Date:  2018-06-12       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.